New insights into the management of renal cell cancer

Oncology (Switzerland)

Volumn 84, Issue 1, 2012, Pages 22-31

  Pécuchet, Nicolas ^a,b   Fournier, Laure S ^a,b   Oudard, Stéphane ^a,b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

HIF; mTOR; Renal cell carcinoma; Targeted therapy; Therapeutic response; Treatment resistance; VEGF; VHL

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; CABOZANTINIB; DOVITINIB; EVEROLIMUS; FIBROBLAST GROWTH FACTOR; FORETINIB; GDC 0980; IMATINIB; INTERFERON; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; MOTESANIB; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RILOTUMUMAB; SCATTER FACTOR RECEPTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER GENETICS; CANCER PROGNOSIS; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; HEALTH ECONOMICS; HUMAN; KIDNEY CARCINOMA; NEPHRECTOMY; NONHUMAN; POLITICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; RISK ASSESSMENT; THERAPY RESISTANCE; TREATMENT RESPONSE; UNITED KINGDOM;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS;

EID: 84867451301     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000342962     Document Type: Review

References (68)

1. Ljungberg B, Campbell SC, Cho HY, Jacqmin D, Lee JE, Weikert S, Kiemeney LA: The epidemiology of renal cell carcinoma. Eur Urol 2011; 60: 615-621
2. Lopez-Beltran A, Carrasco JC, Cheng L, Scarpelli M, Kirkali Z, Montironi R: 2009 update on the classification of enal epithelial tumors in adults. Int J Urol 2009; 16: 432- 443
3. Linehan WM, Srinivasan R, Schmidt LS: The genetic basis of kidney cancer: A metabolic disease. Nat Rev Urol 2010; 7: 277-285
4. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C: Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev 2008; 4: 193-205
5. Kluger N, Giraud S, Coupier I, Avril MF, Dereure O, Guillot B, Richard S, Bessis D: Birt- Hogg-Dubé syndrome: Clinical and genetic studies of 10 French families. Br J Dermatol 2010; 162: 527-537
6. Kaelin WG: The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 2007; 13: 680s-684s.
7. Moore LE, Nickerson ML, Brennan P, Toro JR, Jaeger E, Rinsky J, Han SS, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Schmidt LS, Lenz P, Karami S, Linehan WM, Merino M, Chanock S, Boffetta P, Chow WH, Waldman FM, Rothman N: Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: Associations with germline VHL polymorphisms and etiologic risk factors. PLoS Genet 2011; 7:e1002312
8. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, Davies H, Edkins S, Hardy C, Latimer C, Teague J, Andrews J, Barthorpe S, Beare D, Buck G, Campbell PJ, Forbes S, Jia M, Jones D, Knott H, Kok CY, Lau KW, Leroy C, Lin ML, McBride DJ, Maddison M, Maguire S, McLay K, Menzies A, Mironenko T, Mulderrig L, Mudie L, O'Meara S, Pleasance E, Rajasingham A, Shepherd R, Smith R, Stebbings L, Stephens P, Tang G, Tarpey PS, Turrell K, Dykema KJ, Khoo SK, Petillo D, Wondergem B, Anema J, Kahnoski RJ, Teh BT, Stratton MR, Futreal PA: Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010; 463: 360-363
9. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, Davies H, Jones D, Lin M-L, Teague J, Bignell G, Butler A, Cho J, Dalgliesh GL, Galappaththige D, Greenman C, Hardy C, Jia M, Latimer C, Lau KW, Marshall J, McLaren S, Menzies A, Mudie L, Stebbings L, Largaespada DA, Wessels LFA, Richard S, Kahnoski RJ, Anema J, Tuveson DA, Perez-Mancera PA, Mustonen V, Fischer A, Adams DJ, Rust A, Chan-on W, Subimerb C, Dykema K, Furge K, Campbell PJ, Teh BT, Stratton MR, Futreal PA: Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011; 469: 539-542
10. Wilson BG, Roberts CWM: SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011; 11: 481-492
11. Young AC, Craven RA, Cohen D, Taylor C, Booth C, Harnden P, Cairns DA, Astuti D, Gregory W, Maher ER, Knowles MA, Joyce A, Selby PJ, Banks RE: Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin Cancer Res 2009; 15: 7582-7592
12. Gad S, Lefèvre SH, Khoo SK, Giraud S, Vieillefond A, Vasiliu V, Ferlicot S, Molinié V, Denoux Y, Thiounn N, Chrétien Y, Mejean A, Zerbib M, Benoît G, Hervé JM, Allègre G, Bressac-de Paillerets B, Teh BT, Richard S: Mutations in BHD and TP53 genes, but not in HNF1 - gene, in a large series of sporadic chromophobe renal cell carcinoma. Br J Cancer 2006; 96: 336-340 (Pubitemid 46160640)
13. Shih YC, Chien CR, Xu Y, Pan IW, Smith GL, Buchholz TA: Economic burden of renal cell carcinoma: Part I - an updated review. Pharmacoeconomics 2011; 29: 315-329
14. Shih YC, Chien CR, Xu Y, Pan IW, Smith GL, Buchholz TA: Economic burden of renal cell carcinoma in the US: Part II - an updated analysis. Pharmacoeconomics 2011; 29: 331- 341
15. Thompson Coon J, Hoyle M, Green C, Liu Z, Welch K, Moxham T, Stein K: Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: A systematic review and economic evaluation. Health Technol Assess 2010; 14: 1-208
16. Purmonen T, Martikainen JA, Soini EJO, Kataja V, Vuorinen RL, Kellokumpu-Lehtinen PL: Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland. Clin Ther 2008; 30: 382-392 (Pubitemid 351474383)
17. Chabot I, Rocchi A: How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma. Value ealth 2010; 13: 837-845
18. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garciadel- Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584- 3590
19. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM: Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27: 3312-3318
20. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ: Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206. J Clin Oncol 2010; 28: 2137-2143
21. Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V: Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival. J Clin Oncol 2010; 28: 2144-2150
22. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE: Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial. J Clin Oncol 2010; 28: 1061-1068
23. Escudier BJ, Porta C, Bono P, De Giorgi U, Parikh O, Hawkins RE, Sevin E, Negrier S, Khan S, McCann L, Mehmud F, Cella D: Patient preference between pazopanib (Paz) and sunitinib (Sun): Results of a randomized double-blind, placebo-controlled, crossover study in patients with metastatic renal cell carcinoma (mRCC) - PISCES study, NCT 01064310. J Clin Oncol 2012; 30(suppl; abstr CRA4502).
24. Heng DYC, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, Mcdermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. J Clin Oncol 2009; 27: 5794-5799
25. Bergers G, Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592-603
26. Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL: Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008; 14: 7272-7283
27. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou Y-C, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet 2011; 378: 1931-1939
28. Rixe O, Dutcher J, Motzer RJ, Wilding G, Stadler WM, Garrett M, Pithavala Y, Kim S, Tarazi J, Rini BI: Diastolic blood pressure (dBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC). J Clin Oncol 2012; 27(suppl; abstr 5045).
29. Rini BI, Grünwald V, Fishman M, Melichar B, Ueda T, Karlov P, Bair A, Chen Y, Kim S, Jonasch E: Axitinib for first-line metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study. J Clin Oncol 2012; 30(suppl; abstr 4503).
30. Nosov D, Bhargava P, Esteves WB, Strahs AL, Lipatov ON, Lyulko OO, Anischenko AO, Chacko RT, Doval D, Slichenmyer WJ: Final analysis of the phase II randomized discontinuation trial (RDT) of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma (RCC). J Clin Oncol 2011; 29(suppl; abstr 4550).
31. Motzer RJ, Nosov D, Eisen T, Bondarenko IN, Lesovoy V, Lipatov ON, Tomczak P, Lyulko AA, Alyasova A, Harza M, Kogan M, Alexeev B, Sternberg CN, Szczylik C, Zhang J, Strahs AL, Esteves B, Slichenmyer WJ, Berkenblit A, Hutson TE: Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, openlabel, multicenter trial. J Clin Oncol 2012; 30(suppl; abstr 4501).
32. Casanovas O, Hicklin DJ, Bergers G, Hanahan D: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in latestage pancreatic islet tumors. Cancer Cell 2005; 8: 299-309 (Pubitemid 41443415)
33. Angevin E, Grunwald V, Ravaud A, Castellano DE, Lin CC, Gschwend JE, Harzstark AL, Chang J, Wang Y, Shi MM, Escudier BJ: A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC). J Clin Oncol 2011; 29(suppl; abstr 4551).
34. Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, Lou T, Tan J, Li C, Tam D, Lougheed J, Yakes FM, Bentzien F, Xu W, Zaks T, Wooster R, Greshock J, Joly AH: Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 2009; 69: 8009-8016
35. Gibney G, Conrad P, Aziz SA, Camp RL, Schwartz BE, Chen C, Kelly WK, Kluger HM: C-met as a therapeutic target using ARQ 197 in renal cell carcinoma. J Clin Oncol 2011; 29(suppl 7; abstr 360).
36. Shojaei F, Lee JH, Simmons BH, Wong A, Esparza CO, Plumlee PA, Feng J, Stewart AE, Hu-Lowe DD, Christensen JG: HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res 2010; 70: 10090-10100
37. You W-K, Sennino B, Williamson CW, Falcón B, Hashizume H, Yao L-C, Aftab DT, McDonald DM: VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res 2011; 71: 4758- 4768
38. Smith DC, Smith MR, Small EJ, Sweeney C, Kurzrock R, Gordon MS, Vogelzang NJ, Scheffold C, Ballinger MD, Hussain M: Phase II study of XL184 in a cohort of patients (pts) with castration-resistant prostate cancer (CRPC) and measurable soft tissue disease. J Clin Oncol. 2011; 29(suppl 7; abstr 127).
39. Schöffski P, Garcia JA, Stadler WM, Gil T, Jonasch E, Tagawa ST, Smitt M, Yang X, Oliner KS, Anderson A, Zhu M, Kabbinavar F: A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int 2011; 108: 679- 686
40. Rosen PJ, Sweeney CJ, Park DJ, Beaupre DM, Deng H, Leitch IM, Shubhakar P, Zhu M, Oliner KS, Anderson A, Yee LK: A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clin Cancer Res 2010; 16: 2677-2687
41. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, Scherer SW, Zhuang Z, Lubensky I, Dean M, Allikmets R, Chidambaram A, Bergerheim UR, Feltis JT, Casadevall C, Zamarron A, Bernues M, Richard S, Lips CJ, Walther MM, Tsui LC, Geil L, Orcutt ML, Stackhouse T, Lipan J, Slife L, Brauch H, Decker J, Niehans G, Hughson MD, Moch H, Storkel S, Lerman MI, Linehan WM, Zbar B: Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas Nat Genet 1997; 16: 68-73 (Pubitemid 27198158)
42. Schmidt L, Junker K, Nakaigawa N, Kinjerski T, Weirich G, Miller M, Lubensky I, Neumann HP, Brauch H, Decker J, Vocke C, Brown JA, Jenkins R, Richard S, Bergerheim U, Gerrard B, Dean M, Linehan WM, Zbar B: Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999; 18: 2343-2350 (Pubitemid 29192711)
43. Eder JP, Shapiro GI, Appleman LJ, Zhu AX, Miles D, Keer H, Cancilla B, Chu F, Hitchcock- Bryan S, Sherman L, McCallum S, Heath EI, Boerner SA, LoRusso PM: A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res 2010; 16: 3507-3516
44. Srinivasan R, Linehan W, Vaishampayan U, Logan T, Shankar SM, Sherman LJ, Liu Y, Choueiri TK: A phase II study of two dosing regimens of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in patients (pts) with papillary renal carcinoma (PRC). In J Clin Oncol 2009; 27(suppl; abstr 5103).
45. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A: Phase 3 trial of everolimus for metastatic renal cell carcinoma. Cancer 2010; 116: 4256-4265
46. Jacinto E, Loewith R, Schmidt A, Lin S, Rüegg MA, Hall A, Hall MN: Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6: 1122-1128 (Pubitemid 39468014)
47. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D: Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/ Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: Rationale for therapeutic inhibition of both pathways. Blood 2008; 111: 379- 382
48. Dancey J: MTOR signaling and drug development in cancer. Nat Rev Clin Oncol 2010; 7: 209-219
49. Carew JS, Kelly KR, Nawrocki ST: Mechanisms of mTOR inhibitor resistance in cancer therapy. Targ Oncol 2011; 6: 17-27
50. Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, Signoretti S, Mier JW: The efficacy of the novel dual PI3- kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma Clin Cancer Res 2010; 16: 3628-3638
51. Swanton C, Larkin JM, Gerlinger M, Eklund AC, Howell M, Stamp G, Downward J, Gore M, Futreal PA, Escudier B, Andre F, Albiges L, Beuselinck B, Oudard S, Hoffmann J, Gyorffy B, Torrance CJ, Boehme KA, Volkmer H, Toschi L, Nicke B, Beck M, Szallasi Z: Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Med 2010; 2: 53
52. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED: Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis. J Urol 2004; 171: 1071-1076 (Pubitemid 38327529)
53. Escudier B, Kataja V, on behalf of the ESMO Guidelines Working Group: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21:v137-v139
54. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IGH, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global ARCC Trial: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281 (Pubitemid 46849157)
55. van der Poel H, Roukema J, Horenblas S, Debruyne F: Metastasectomy in renal cell carcinoma: A multicenter retrospective analysis Eur Urol 1999; 35: 197-203 (Pubitemid 29108145)
56. Alt AL, Boorjian SA, Lohse CM, Costello BA, Leibovich BC, Blute ML: Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer 2011; 117: 2873-2882
57. Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM: Metastasectomy After Targeted Therapy in Patients With Advanced Renal Cell Carcinoma J Urol 2010; 185: 439-444
58. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216
59. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134 (Pubitemid 46089673)
60. Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Hariharan S, Lee S-H, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Nieto A, Yuan J, Bukowski R: Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: An expanded- access trial. Lancet Oncol 2009; 10: 757-763
61. Ward JE, Stadler WM: Pazopanib in renal cell carcinoma. Clin Cancer Res 2010; 16: 5923-5927
62. Fournier LS, Oudard S, Thiam R, Trinquart L, Banu E, Medioni J, Balvay D, Chatellier G, Frija G, Cuenod CA: Metastatic renal carcinoma: Evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology 2010; 256: 511-518
63. Thiam R, Fournier LS, Trinquart L, Medioni J, Chatellier G, Balvay D, Escudier B, Dromain C, Cuenod CA, Oudard S: Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann Oncol 2010; 21: 936-941
64. Thiam R, Cuenod C, Fournier L, Lamuraglia M, Medioni J, Barascout B, Scotté F, Fabre- Guillevin E, Oudard S: Determination of a new RECIST threshold using everolimus treatment in metastatic renal cell carcinoma: Evaluation from the RECORD-1 study. Ann Oncol 2010; 21(suppl; abstr 4147).
65. Lucidarme O, Lamuraglia M, Escudier B, Ravaud A, Rolland F, Chevreau C, Negrier S, Duclos B, K S, Oudard S: Interest of CHOI and modified CHOI criterion for evaluation of mRCC patients treated with Everolimus Cancer Imaging 2011; 11:S41-S42
66. d'Assignies G, Couvelard A, Bahrami S, Vullierme MP, Hammel P, Hentic O, Sauvanet A, Bedossa P, Ruszniewski P, Vilgrain V: Pancreatic endocrine tumors: Tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors Radiology 2009; 250: 407-416
67. Padhani AR, Neeman M: Challenges for imaging angiogenesis. Br J Radiol 2001; 74: 886- 890 (Pubitemid 33064630)
68. Lamuraglia M, Escudier B, Chami L, Schwartz B, Leclère J, Roche A, Lassau N: To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: Pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer 2006; 42: 2472-2479 (Pubitemid 44442955)